GlassScriptPhysician profile
Renee V Gardner
NPI 1629089149
$24,679.58
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $729 · 2020: $3,909 · 2021: $10K · 2022: $4,978 · 2023: $4,795 · 2024: $85.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,960 · Travel and Lodging: $1,095 · Food and Beverage: $726 · Education: $98.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,960.00 |
| Travel and Lodging | $1,095.22 |
| Food and Beverage | $726.42 |
| Education | $98.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $18,353.50 | 2020-2022 | |
| Pfizer INC. | $4,545.04 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $232.43 | 2019-2023 | |
| Csl Behring | $185.40 | 2019-2023 | Idelvion |
| Novo Nordisk INC | $152.40 | 2019-2022 | |
| Servier Pharmaceuticals LLC | $143.90 | 2019-2021 | |
| Seagen INC. | $139.80 | 2023 | Adcetris |
| Sobi, INC | $138.54 | 2019-2023 | |
| Bioverativ Therapeutics INC. | $110.26 | 2019 | |
| Emd Serono, INC. | $100.15 | 2019 | |
| Alexion Pharmaceuticals, INC. | $77.78 | 2019-2023 | Ultomiris |
| Emmaus Medical, INC. | $72.98 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.80 | 2022 | |
| Octapharma USA, INC. | $55.13 | 2022-2023 | Nuwiq |
| Jazz Pharmaceuticals INC. | $42.66 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Y-Mabs Therapeutics, INC. | $31.34 | 2023 | Danyelza |
| Btg International INC. | $28.92 | 2020-2023 | |
| Fennec Pharmaceuticals, INC. | $27.90 | 2023 | Pedmark |
| Axogen | $24.25 | 2019 | |
| Epizyme, INC. | $21.31 | 2021 | |
| Grifols USA, LLC | $19.67 | 2019 | |
| Chiesi USA, INC. | $19.48 | 2020 | |
| Rare Disease Therapeutics, INC. | $18.36 | 2019 | |
| Shire North American Group INC | $16.77 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.52 | 2021 | |
| Medexus Pharma, INC. | $15.00 | 2021 | |
| Duchesnay USA Incorporated | $13.19 | 2019 | |
| Silvergate Pharmaceuticals, INC. | $12.10 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.